Contribution: Industrial Research Assistance Program
Jenthera Therapeutics Inc.
$500,000.00
MNC Collab – 34 - SC: In vivo Editing Strategy for Treatment of Sickle Cell Anemia
FY 2025-26 · 2026-01-05
Summary
The MNC Collab – 34 - SC project approach requires the systemic administration of a proprietary gene editing complex. This complex will target progenitor cells within the peripheral blood and bone marrow to perform an in-vivo edit of the BCL11A enhancer, effectively reactivating the expression of fetal hemoglobin aiming at a beneficial therapeutic outcome.
Department
Program
Industrial Research Assistance Program
Recipient
Location
Cote-Saint-Luc|Côte Saint-Luc, Quebec, Canada
Recipient Type
For-profit organization
Business Number
701783482
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2028-01-03
Agreement Number
1039998
Agreement Start Date
2026-01-05
Agreement Title
MNC Collab – 34 - SC: In vivo Editing Strategy for Treatment of Sickle Cell Anemia
Agreement Title (French)
PCM – 34 - SC : Stratégie d’édition in vivo pour le traitement de la drépanocytose
Agreement Type
Contribution
Agreement Value
$500,000.00
Amendment Number
0
Coverage
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity. | Les projets du Programme d'aide à la recherche industrielle favorisent la création de richesse au Canada grâce à l'innovation technologique et renforcent l'écosystème canadien de l'innovation en créant de nouvelles capacités industrielles.
Description
The MNC Collab – 34 - SC project approach requires the systemic administration of a proprietary gene editing complex. This complex will target progenitor cells within the peripheral blood and bone marrow to perform an in-vivo edit of the BCL11A enhancer, effectively reactivating the expression of fetal hemoglobin aiming at a beneficial therapeutic outcome.
Description (French)
L’approche du projet PCM – 34 - SC repose sur l’administration systémique d’un complexe exclusif d’édition génétique. Ce complexe ciblera les cellules progénitrices présentes dans le sang périphérique et la moelle osseuse afin de procéder à une édition in vivo de l’amplificateur BCL11A, réactivant ainsi efficacement l’expression de l’hémoglobine fœtale dans le but d’obtenir un résultat thérapeutique bénéfique.
Expected Results
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Expected Results (French)
Les résultats attendus du Programme d’aide à la recherche industrielle du CNRC sont axés sur la croissance des petites et moyennes entreprises (PME) grâce à l’innovation et à la création de richesse pour le Canada.
Federal Riding
Mount Royal
Federal Riding (French)
Mont-Royal
Federal Riding Number
24052
NAICS Code
339110
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program
Program Name (French)
Programme d’aide à la recherche industrielle
Program Purpose
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Program Purpose (French)
Les contributions versées aux entreprises en vertu du Programme d’aide à la recherche industrielle ont pour objectif d’apporter un soutien aux petites et moyennes entreprises (PME) afin qu’elles puissent approfondir leurs connaissances en matière d’innovation et renforcer leur capacité d’innovation, de croissance et de création de richesse pour le Canada.
Recipient Business Number
701783482
Recipient City
Cote-Saint-Luc|Côte Saint-Luc
Recipient Country
CA
Recipient Legal Name
Jenthera Therapeutics Inc.
Recipient Operating Name
Jenthera Therapeutics Inc.
Recipient Postal Code
H4W 1K7
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2025-2026-Q4-1039998
